Related Experiment Video
Updated: Aug 16, 2026

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
Published on: May 21, 2018
Non-cardiogenic pulmonary oedema induced by salazosulfapyridine
Takashi Saito1, Yoshihiro Mori, Mitsuo Yoshida
1Department of Internal Medicine, Federation of Public Services and Affiliated Personnel Aid Associations, Takamatsu Hospital, Kagawa, Japan. saitoh@kkr-ta-hp.gr.jp
Abstract:
A 25-year-old woman received oral salazosulfapyridine, 4 g/day, for treatment of ulcerative colitis. At 10 days later, she presented with fever and respiratory symptoms. Based on physical, laboratory and radiological findings, bacterial pneumonia and non-cardiogenic pulmonary oedema was suspected. Salazosulfapyridine was immediately halted and antibiotic therapy started. Two days later, her symptoms and abnormal findings had improved rapidly. Bacteriological studies were negative. Salazosulfapyridine-induced non-cardiogenic pulmonary oedema was diagnosed. Non-cardiogenic pulmonary oedema should be considered as one of several salazosulfapyridine- induced pulmonary diseases in patients who are receiving salazosulfapyridine and who develop respiratory symptoms and an abnormal CXR.
Related Concept Videos
Pulmonary Edema II: Pathophysiology
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Nephrotic Syndrome I : Introduction
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
